{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058240","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.332505+00:00","generated_at":"2026-06-09T00:05:03.439517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ultragenyx Q3 revenue $98.1M (+8% YoY); reaffirms FY2023 guidance $425-450M","bullets":["Total revenue $98.1M, up 8% YoY; Crysvita $74.9M, Dojolvi $16.6M.","Net loss $159.6M ($2.23/share), improved from $245.1M ($3.50/share) in Q3 2022.","Cash $524.2M at Sept 30; net $326.5M from October offering.","FY2023 guidance reaffirmed: total revenue $425-450M, Crysvita $325-340M, Dojolvi $65-75M.","Clinical: UX143 (OI) 67% fracture rate reduction; GTX-102 (Angelman) improvements; UX701 (Wilson) patients tapering."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058240","json":"https://secwatch.observer/filing/0000950170-23-058240.json","markdown":"https://secwatch.observer/filing/0000950170-23-058240.md","text":"https://secwatch.observer/filing/0000950170-23-058240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023058240/0000950170-23-058240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023058240/rare-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:05:03.439517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a76eed2af84831e2118628ee11841d6fe42ab906","claim":"Ultragenyx Pharmaceutical Inc. reported the quarter ended September 30, 2023 results: revenue $98.1 million. Guidance reaffirmed.","evidence_excerpt":"Higa ir@ultragenyx.com Media Jeff Blake media@ultragenyx.com Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $ 16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023058240/0000950170-23-058240-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$98.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}